产品收入情况 - 2024年第三季度总净产品收入为1.048亿美元同比增长81%[2] - 2024年第三季度Auvelity净产品销售额为8040万美元同比增长113%[3] - 2024年第三季度Sunosi净产品收入为2440万美元同比增长21%[3] - 2024年三季度产品销售净额为103736千美元2023年同期为57127千美元[34] - 2024年前三季度产品销售净额为264352千美元2023年同期为131713千美元[34] 产品相关计划与试验结果公布 - 计划2025年第一季度第二次扩充Auvelity精神病学销售团队[1] - 2025年1月31日为AXS - 07治疗偏头痛的PDUFA目标日期[1] - 预计2024年第四季度公布AXS - 05在阿尔茨海默病躁动中的ADVANCE - 2和ACCORD - 2 3期试验的主要结果[1] - 预计2024年第四季度公布AXS - 12在发作性睡病中的ENCORE 3期试验的主要结果[1] - 预计2025年1月公布solriamfetol在ADHD中的FOCUS 3期试验的主要结果[1] - 预计2025年1月公布solriamfetol在MDD中的PARADIGM 3期试验的主要结果[1] - 预计2024年11月提交AXS - 14用于纤维肌痛管理的NDA[1] 公司财务状况 - 2024年三季度净亏损64602千美元2023年同期为62199千美元[34] - 2024年前三季度净亏损212304千美元2023年同期为140587千美元[34] - 2024年三季度末现金及现金等价物为327341千美元2023年末为386193千美元[33] - 2024年三季度末总资产为561458千美元2023年末为588236千美元[33] - 2024年三季度末总负债为468560千美元2023年末为397259千美元[33] 公司风险与不确定因素 - 公司存在多种前瞻性陈述包含产品商业成功、临床试验、监管批准等多方面风险[31] - 公司面临如维持和扩大付款人覆盖范围等多种能力相关风险[31] - 公司面临如成功捍卫知识产权等多种不确定因素[31]

The third-quarter 2024 reporting cycle of the Medical sector is about to end as most firms have already reported their earnings results. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off around mid-October when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently raised its total revenue expectation for the year while lowering its adjusted earnings e ...

Yes, bargains can still be found in the stock market.How richly valued are stocks right now? Legendary investor Warren Buffett has built Berkshire Hathaway's cash stockpile up to roughly $277 billion. When Buffett is sitting on that much cash because he can't find appealing investments to buy, you know stocks are expensive. There are exceptions, though. In a market that's broadly speaking priced for perfection, three Motley Fool contributors have identified what they think are bargain stocks to buy: Axsome ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate i ...

Axsome Therapeutics’ (AXSM) Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand.AXSM is also conducting several label expansion studies on Auvelity targeting other central nervous system (CNS) disorders like Alzheimer’s disease (AD) associated agitation an ...

It could be an industry giant in the making.Companies with exciting prospects aren't always of the popular, headline-grabbing variety. Some little-known stocks are worth serious consideration, too.Take Axsome Therapeutics (AXSM), a mid-cap biotech company not involved in the rapidly growing area of GLP-1 weight loss drugs. Though it's doing so quietly, this drugmaker has performed more or less in line with the broader market this year, and there are good reasons to believe it could produce strong returns ov ...

Axsome Therapeutics, Inc. (AXSM) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.Year to date, shares of Axsome have rallied 20.1% against the industry’s decrease of 0.9%.Image Source: Zacks Invest ...

A month has gone by since the last earnings report for Axsome Therapeutics (AXSM) . Shares have added about 4.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Axsome due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Axsome Q2 Loss Widens Y/Y, Revenues Beat Estimat ...

Axsome Therapeutics’ (AXSM) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.Axsome is also conducting several label expansion studies on Auvelity targeting other centra ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company. Axs ...